Menu Expand
PET in the Aging Brain, An Issue of PET Clinics - E-Book

PET in the Aging Brain, An Issue of PET Clinics - E-Book

Andrew B. Newberg | Abass Alavi

(2010)

Additional Information

Book Details

Abstract

PET imaging has shown its value in diagnosing diseases affecting older people. Most significantly this has been with regard to the diagnosis of Alzheimer’s disease and other forms of dementia. Parkinson’s disease is another condition in which PET has proved valuable. This issue also included articles on the uses of PET for diagnosing cerebrovascular disease and for assessing neuroplasticity.

Table of Contents

Section Title Page Action Price
Front Cover Cover
Contributors iii
Contents v
PET Clinics viii
Preface xi
Chapter 1. Normal Patterns and Variants in PET Brain Imaging 1
NORMAL VARIANTS IN FUNCTIONAL NEUROIMAGING STUDIES 2
NEUROIMAGING IN THE STUDY OF NORMAL AGING FROM INFANCY TO ADULTHOOD 4
NEUROTRANSMITTER FUNCTION IN NORMAL AGING 8
OTHER BIOCHEMICAL CHANGES IN NORMAL AGING 10
SUMMARY 10
REFERENCES 10
Chapter 2. Evaluation of Early Dementia (Mild Cognitive Impairment) 15
FDG-PET STUDIES 16
‘‘AT RISK’’ POPULATIONS 17
AMYLOID PET IMAGING 20
PIB 20
FDDNP 22
COMPARATIVE STUDIES 22
LIMITATIONS 24
SUMMARY 26
REFERENCES 27
Chapter 3. Amyloid PET Ligands for Dementia 33
ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 33
AMYLOID LIGANDS 34
AMYLOID IMAGING IN DEMENTIA 38
AMYLOID IMAGING AND OTHER MARKERS OF DISEASE 40
SPECIFIC BIOMARKERS OF DISEASE 41
SUMMARY 43
REFERENCES 44
Chapter 4. 18F-Fluorodeoxyglucose PET in the Evaluation of Parkinson Disease 55
METABOLIC NETWORKS IN PARKINSONISM 56
METABOLIC PATTERNS IN ATYPICAL PARKINSONIAN SYNDROMES 57
DIFFERENTIAL DIAGNOSIS USING PET 58
CHANGES IN NETWORK ACTIVITY WITH DISEASE PROGRESSION IN PD 59
NETWORK MODULATION WITH PD THERAPY 60
SUMMARY 62
ACKNOWLEDGMENTS 62
REFERENCES 63
Chapter 5. SPECT and PET in Atypical Parkinsonism 65
THE SPECTRUM OF MOVEMENT DISORDERS 65
DOPAMINERGIC IMAGING IN THE DIAGNOSIS OF PARKINSONISM AND RELATED DISORDERS 66
NONDOPAMINERGIC IMAGING IN THE DIFFERENTIAL DIAGNOSIS OF MOVEMENT DISORDERS 70
IDENTIFYING NEW TARGETS AND IMAGING BIOMARKERS IN PARKINSON SPECTRUM DISORDERS 71
SUMMARY 72
REFERENCES 73
Chapter 6. 18F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons 75
APPROACHES TO DA NEURON IMAGING 75
VMAT2 AS PET IMAGING TARGET 76
REFERENCES 80
Chapter 7. PET in Cerebrovascular Disease 83
NORMAL CEREBRAL HEMODYNAMICS AND ENERGY METABOLISM 83
CEREBROVASCULAR CONTROL 84
HEMODYNAMIC EFFECTS OF ARTERIAL OCCLUSIVE DISEASE 86
EVOLUTION OF ACUTE INFARCTION 89
IDENTIFICATION OF PREVENTABLE INFARCTION 90
CAROTID ARTERY ATHEROSCLEROSIS 92
REMOTE METABOLIC EFFECTS OF CEREBRAL INFARCTION 92
VASCULAR DEMENTIA 94
INTRACEREBRAL HEMORRHAGE 94
ANEURYSMAL SUBARACHNOID HEMORRHAGE 94
SUMMARY 97
REFERENCES 97
Chapter 8. Imaging Pathophysiology and Neuroplasticity After Stroke 107
CEREBROVASCULAR DISEASE 107
EVALUATION OF CBF, METABOLISM, AND RECEPTORS USING PET TRACERS 108
METABOLISM, OEF, AND CEREBROVASCULAR REACTIVITY MEASUREMENTS OF PERIINFARCTION TISSUE HEMODYNAMICS 109
EVALUATION OF ISCHEMIA BY PET 109
PET MEASURES OF CBF AND OEF 109
TIME-DEPENDENT PROGRESSIVELY EVOLVING STROKE PENUMBRA 110
PET MEASURES OF CEREBRAL TISSUE VIABILITY STATUS IN ISCHEMIC BRAIN 111
RECOVERY FROM STROKE: DIASCHISIS RESOLUTION AND CEREBRAL REORGANIZATION 112
CEREBRAL DIASCHISIS AS A RESULT OF STROKE 112
IMPROVEMENT OF STROKE-INDUCED NEUROLOGIC DEFICITS ATTRIBUTABLE TO CEREBRAL DIASCHISIS RESOLUTION 114
CEREBRAL REORGANIZATION 115
IMPROVEMENT OF STROKE-INDUCED NEUROLOGIC DEFICITS ATTRIBUTABLE TO CEREBRAL REORGANIZATION 116
ADAPTIVE PLASTICITY IN STROKE RECOVERY 117
EXPANSION OF CORTICAL REPRESENTATION AREAS AND ROLE OF THE CONTRALESIONAL HEMISPHERE 118
TASK-DEPENDENT CORTICAL ACTIVATION STUDIES 119
SUMMARY 123
ACKNOWLEDGMENTS 123
REFERENCES 123
Index 127